| Delaware | | | 81-3405262 | | |||
| (State or other jurisdiction of incorporation or organization) | | | (I.R.S. Employer Identification Number) | |
| Large accelerated filer | | | ☐ | | | Accelerated filer | | | ☐ | |
| Non-accelerated filer | | | ☒ | | | Smaller reporting company | | | ☒ | |
| | | | | | | Emerging growth company | | | ☒ | |
| | | | | 1 | | | |
| | | | | | | ||
| | | | | 3 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | |
| | | Beneficial Ownership Before this Offering | | | Shares Offered Hereby | | | Beneficial Ownership After this Offering | | |||||||||||||||||||||
Selling Stockholder | | | Number of Shares Owned | | | Percentage of Outstanding Shares | | | Number of Shares Owned(1) | | | Percentage of Outstanding Shares | | ||||||||||||||||||
Venrock Healthcare Capital Partners III, L.P.(2)(3) | | | | | 5,562,447 | | | | | | 8.98% | | | | | | 5,562,447 | | | | | | — | | | | | | — | | |
VHCP Co-Investment Holdings III, LLC(2)(4) | | | | | 556,456 | | | | | | * | | | | | | 556,456 | | | | | | — | | | | | | — | | |
Venrock Healthcare Capital Partners EG, L.P(2)(5) | | | | | 15,039,131 | | | | | | 21.84% | | | | | | 15,039,131 | | | | | | — | | | | | | — | | |
PB SPV-I LLC(6) | | | | | 3,703,223 | | | | | | 6.06% | | | | | | 3,703,223 | | | | | | — | | | | | | — | | |
Propel Bio Partners LP(7) | | | | | 3,432,824 | | | | | | 5.84% | | | | | | 1,058,063 | | | | | | 2,374,761 | | | | | | 4.11% | | |
Richard & Suzanne Kayne Living Trust dtd 01/14/1999(8) | | | | | 2,645,163 | | | | | | 4.40% | | | | | | 2,645,163 | | | | | | — | | | | | | — | | |
Franklin Strategic Series – Franklin Biotechnology Discovery Fund(9) | | | | | 5,026,154 | | | | | | 8.34% | | | | | | 1,008,400 | | | | | | 4,017,754 | | | | | | 6.66% | | |
Franklin Templeton Investment Funds – Franklin Biotechnology Discovery Fund(10) | | | | | 10,420,578 | | | | | | 16.57% | | | | | | 2,162,848 | | | | | | 8,257,730 | | | | | | 13.13% | | |
Total(11): | | | | | 46,385,976 | | | | | | 53.10% | | | | | | 31,735,731 | | | | | | 14,650,245 | | | | | | 22.42% | | |
| Securities and Exchange Commission Registration Fee | | | $ | 38,940 | | | Securities and Exchange Commission Registration Fee | | | $ | 16,400 | | | ||
| FINRA Filing Fee | | | $ | 45,500 | | | FINRA Filing Fee | | | | 45,500 | | | ||
| Accounting Fees and Expenses | | | $ | 15,000 | | | Accounting Fees and Expenses | | | | 15,000 | | | ||
| Legal Fees and Expenses | | | $ | 150,000 | | | Legal Fees and Expenses | | | | 150,000 | | | ||
| Printing Fees | | | $ | 10,000 | | | Printing Fees | | | | 10,000 | | | ||
| Transfer Agents and Trustees’ Fees and Expenses | | | $ | 20,000 | | | Transfer Agents and Trustees’ Fees and Expenses | | | | 20,000 | | | ||
| Miscellaneous | | | $ | 20,560 | | | Miscellaneous | | | | 20,000 | | | ||
| Total | | | $ | 300,000 | | | Total | | | $ | 276,900 | | |
| Exhibit No. | | | Description | |
| 25.1* | | | Statement of Eligibility on Form T-1 of trustee under the Indenture. | |
| 107 | | | |
| | | | APPLIED THERAPEUTICS, INC. | | | | | |||
| | | | By: | | | /s/ Shoshana Shendelman | | | ||
| | | | | | | Shoshana Shendelman, Ph.D. President and Chief Executive Officer | | |
| Name | | | Title | | | Date | |
| / Shoshana Shendelman, Ph.D. | | | President and Chief Executive Officer (Principal Executive Officer) | | | | |
| | | | Chief (Principal Accounting Officer and Interim Principal Financial Officer) | | | | |
| ||||||||
Les Funtleyder | | | Director | | | | ||
| ||||||||
Teena Lerner, Ph.D. | | | Director | | | | ||
| Stacy Kanter | | | Director | | | May 12, 2023 | |
| /s/ Joel S. Marcus Joel S. Marcus | | | Director | | | | |
| Jay S. Skyler, M.D., MACP | | | Director | | |
|